ILINA BUCUR: Open Payments
NPI 1881140440 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$724 in 35 payments from 7 companies in 2025. Trend: 2023 $16 · 2024 $241 · 2025 $724
Food & beverage: $539Education: $185
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $325 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $164 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| E.R. Squibb & Sons, L.L.C. | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Neurocrine BioSciences, Inc. | 1 | $37 |
| Alkermes, Inc. | 1 | $21 |
Products named: CAPLYTA, AUSTEDO XR, COBENFY, Auvelity, UZEDY, REXULTI, INGREZZA, ARISTADA.
Industry payments across WA — which companies pay providers there.
